These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22928914)

  • 1. Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
    Huang H; La DS; Cheng AC; Whittington DA; Patel VF; Chen K; Dineen TA; Epstein O; Graceffa R; Hickman D; Kiang YH; Louie S; Luo Y; Wahl RC; Wen PH; Wood S; Fremeau RT
    J Med Chem; 2012 Nov; 55(21):9156-69. PubMed ID: 22928914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.
    Chen JJ; Liu Q; Yuan C; Gore V; Lopez P; Ma V; Amegadzie A; Qian W; Judd TC; Minatti AE; Brown J; Cheng Y; Xue M; Zhong W; Dineen TA; Epstein O; Human J; Kreiman C; Marx I; Weiss MM; Hitchcock SA; Powers TS; Chen K; Wen PH; Whittington DA; Cheng AC; Bartberger MD; Hickman D; Werner JA; Vargas HM; Everds NE; Vonderfecht SL; Dunn RT; Wood S; Fremeau RT; White RD; Patel VF
    Bioorg Med Chem Lett; 2015 Feb; 25(4):767-74. PubMed ID: 25613679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.
    Gravenfors Y; Viklund J; Blid J; Ginman T; Karlström S; Kihlström J; Kolmodin K; Lindström J; von Berg S; von Kieseritzky F; Bogar K; Slivo C; Swahn BM; Olsson LL; Johansson P; Eketjäll S; Fälting J; Jeppsson F; Strömberg K; Janson J; Rahm F
    J Med Chem; 2012 Nov; 55(21):9297-311. PubMed ID: 23017051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    Dineen TA; Weiss MM; Williamson T; Acton P; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dunn RT; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; San Miguel T; Sickmier EA; Vargas HM; Wahl RC; Wen PH; Whittington DA; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
    J Med Chem; 2012 Nov; 55(21):9025-44. PubMed ID: 22468684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoimidazoles as BACE-1 inhibitors: the challenge to achieve in vivo brain efficacy.
    Swahn BM; Holenz J; Kihlström J; Kolmodin K; Lindström J; Plobeck N; Rotticci D; Sehgelmeble F; Sundström M; Berg Sv; Fälting J; Georgievska B; Gustavsson S; Neelissen J; Ek M; Olsson LL; Berg S
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1854-9. PubMed ID: 22325942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloid.
    Weiss MM; Williamson T; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dineen TA; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; Rattan C; San Miguel T; Sickmier EA; Wahl RC; Wen PH; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
    J Med Chem; 2012 Nov; 55(21):9009-24. PubMed ID: 22468639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor.
    Cumming JN; Smith EM; Wang L; Misiaszek J; Durkin J; Pan J; Iserloh U; Wu Y; Zhu Z; Strickland C; Voigt J; Chen X; Kennedy ME; Kuvelkar R; Hyde LA; Cox K; Favreau L; Czarniecki MF; Greenlee WJ; McKittrick BA; Parker EM; Stamford AW
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2444-9. PubMed ID: 22390835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides.
    Rueeger H; Lueoend R; Rogel O; Rondeau JM; Möbitz H; Machauer R; Jacobson L; Staufenbiel M; Desrayaud S; Neumann U
    J Med Chem; 2012 Apr; 55(7):3364-86. PubMed ID: 22380629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Barnes K; Johnson M; Hui Y; Turner J; Hu Y; Wagner E; Fan K; Olland A; Bard J; Robichaud AJ
    J Med Chem; 2009 Oct; 52(20):6314-23. PubMed ID: 19757823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of potent and selective BACE-1 inhibitors.
    Björklund C; Oscarson S; Benkestock K; Borkakoti N; Jansson K; Lindberg J; Vrang L; Hallberg A; Rosenquist A; Samuelsson B
    J Med Chem; 2010 Feb; 53(4):1458-64. PubMed ID: 20128595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis.
    Gerritz SW; Zhai W; Shi S; Zhu S; Toyn JH; Meredith JE; Iben LG; Burton CR; Albright CF; Good AC; Tebben AJ; Muckelbauer JK; Camac DM; Metzler W; Cook LS; Padmanabha R; Lentz KA; Sofia MJ; Poss MA; Macor JE; Thompson LA
    J Med Chem; 2012 Nov; 55(21):9208-23. PubMed ID: 23030502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of cell potent BACE-1 inhibitors: structure-activity relationship of P1' substituents.
    Sealy JM; Truong AP; Tso L; Probst GD; Aquino J; Hom RK; Jagodzinska BM; Dressen D; Wone DW; Brogley L; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Dappen MS; Toth G; Pan H; Ruslim L; Miller J; Bova MP; Sinha S; Quinn KP; Sauer JM
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6386-91. PubMed ID: 19811916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel warhead against beta-secretase through fragment-based lead generation.
    Geschwindner S; Olsson LL; Albert JS; Deinum J; Edwards PD; de Beer T; Folmer RH
    J Med Chem; 2007 Nov; 50(24):5903-11. PubMed ID: 17985861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.
    Efremov IV; Vajdos FF; Borzilleri KA; Capetta S; Chen H; Dorff PH; Dutra JK; Goldstein SW; Mansour M; McColl A; Noell S; Oborski CE; O'Connell TN; O'Sullivan TJ; Pandit J; Wang H; Wei B; Withka JM
    J Med Chem; 2012 Nov; 55(21):9069-88. PubMed ID: 22468999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    Epstein O; Bryan MC; Cheng AC; Derakhchan K; Dineen TA; Hickman D; Hua Z; Human JB; Kreiman C; Marx IE; Weiss MM; Wahl RC; Wen PH; Whittington DA; Wood S; Zheng XM; Fremeau RT; White RD; Patel VF
    J Med Chem; 2014 Dec; 57(23):9796-810. PubMed ID: 25389560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Erdei J; Gunawan I; Turner J; Hu Y; Wagner E; Fan K; Chopra R; Olland A; Bard J; Jacobsen S; Magolda RL; Pangalos M; Robichaud AJ
    J Med Chem; 2010 Feb; 53(3):1146-58. PubMed ID: 19968289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
    Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.